Product Data Sheet

LCMV GP (61-80)

Cat. No.:	HY-P2560			
CAS No.:	232598-19-5			
Molecular Formula:	$C_{108}H_{160}N_{24}O_{31}$			
Molecular Weight:	2290.6			
Sequence:	Gly-Leu-Lys-Gly-Pro-Asp-Ile-Tyr-Lys-Gly-Val-Tyr-Gln-Phe-Lys-Ser-Val-Glu-Phe-Asp			
Sequence Shortening:	GLKGPDIYKGVYQFKSVEFD			
Target:	Arenavirus			
Pathway:	Anti-infection			
Storage:	Sealed storage, away from moisture and light, under nitrogen			
	Powder -80°	°C	2 years	
	-20°	°C	1 year	
	* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture			
	and light, under nitrogen)			

BIOLOGICAL ACTIVITY

Description

LCMV GP (61-80) is a peptide fragment derived from lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP), and corresponds to amino acids 61-80. LCMV GP (61-80) is a specific epitope which can induce CD4⁺ T-cell response^{[1][2][3]}.

REFERENCES

[1]. Rodriguez F, et, al. CD4(+) T cells induced by a DNA vaccine: immunological consequences of epitope-specific lysosomal targeting. J Virol. 2001 Nov; 75(21): 10421-30.

[2]. Andargachew R, et, al. CD4 T Cell Affinity Diversity Is Equally Maintained during Acute and Chronic Infection. J Immunol. 2018 Jul 1; 201(1):19-30.

[3]. Homann D, et, al. Mapping and restriction of a dominant viral CD4+T cell core epitope by both MHC class I and MHC class II. Virology. 2007 Jun 20; 363(1): 113-23.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898Fax: 609-228-5909E-mail: tech@MedChemExpress.comAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

